Dendreon reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Dendreon Corp. at market outperform after prostate cancer experts expressed enthusiasm for the company's Provenge and its demonstrated survival benefit. The physician experts believe Provenge also could be combined with other therapies given its novel mechanism and low toxicity. Interim data from the phase 3 Protect study is expected in the second half of this year. Shares of the Seattle biotechnology company were up $0.15, or 3.98%, at $3.92 on volume of 1,249,693 shares versus the three-month running average of 776,960 shares. (Nasdaq: DNDN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.